Marksans Pharma rises as its arm receives marketing authorization for Gabapentin
Marksans Pharma is currently trading at Rs. 239.00, up by 0.80 points or 0.34% from its previous closing of Rs. 238.20 on the BSE.
The scrip opened at Rs. 238.00 and has touched a high and low of Rs. 243.40 and Rs. 236.90 respectively. So far 25307 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 358.50 on 02-Dec-2024 and a 52 week low of Rs. 130.15 on 04-Jun-2024.
Last one week high and low of the scrip stood at Rs. 243.40 and Rs. 216.15 respectively. The current market cap of the company is Rs. 10830.61 crore.
The promoters holding in the company stood at 43.87%, while Institutions and Non-Institutions held 26.76% and 29.37% respectively.
Marksans Pharma’s wholly owned subsidiary in UK -- Relonchem has received marketing authorization for the product Gabapentin 50 mg/ml oral solution from UK Medicines & Healthcare Products Regulatory Agency.
Marksans Pharma is engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulation in the global markets.
